Alberts 1987.

Methods	Randomised Phase II trial
Participants	119 women with incurable squamous cell carcinoma unsuitable for surgery or radiotherapy. No previous chemotherapy exposure
Interventions	Arm 1: mitomycin C 10 mg/m2 iv d2, 44, vincristine 0.5 mg/m2 iv d2, 4, 44, 46, bleomycin 30 mg continuous iv infusion over 24 h for 4 days d1‐4, 43‐46, cisplatin 50 mg/m2 iv d1, 22, 43, 64 Arm 2: mitomycin C 12 mg/m2 iv d1, 43, cisplatin 50 mg/m2 iv d1, 22, 43, 64 Arm 3: cisplatin 50 mg/m2 iv d1, 22, 43, 64
Outcomes	Response rate Response duration Median survival Toxicity (SWOG)
Notes	5 ineligible patients (reasons not stated). Arm 3 stopped early owing to slow accrual. Not clear whether ITT analysis performed
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not documented
Allocation concealment (selection bias)	Unclear risk	Not documented
Blinding (performance bias and detection bias) All outcomes	High risk	Not documented
Incomplete outcome data (attrition bias) All outcomes	Low risk	5 ineligible patients (reasons not stated). Arm 3 stopped early owing to slow accrual. Not clear whether ITT analysis performed
Selective reporting (reporting bias)	Unclear risk	Insufficient information
Other bias	High risk	Cisplatin arm stopped early despite appearing to have better results so only 9 patients evaluable